Effects of Esketamine on Oxygenation and Quality of Recovery in Patients Undergoing Thoracoscopic Surgery
NCT ID: NCT06822088
Last Updated: 2025-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
126 participants
INTERVENTIONAL
2025-03-01
2026-03-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Esketamine Combined With Dexmedetomidine on Postoperative Recovery Quality in Patients Undergoing Thoracoscopic Surgery
NCT07125573
Safety and Efficacy of Esketamine Combined With Dexmedetomidine for Sedation of Mechanically Ventilated Patients
NCT05466708
An Exploratory Study of Esketamine in Patients After Thoracoscopic Surgery
NCT05458453
Impact of Perioperative Dexmedetomidine and Esketamine on Postoperative Quality of Recovery
NCT07308756
Esketamine Induction Intubation in ICU Patients.
NCT05464979
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Method：A total of 126 patients undergoing elective thoracoscopic surgery under general anesthesia were randomly divided into three groups: normal saline group (Group C), dexmedetomidine group (Group D), and esketamine group (Group E),with 42 patients in each group.In Group C,an equal volume of normal saline was continuously infused. In Group D,a loading dose of dexmedetomidine (1 μg/kg) was administered 10 min before induction of anesthesia, followed by a continuous infusion at a rate of 0.4 μg·kg-1·h-1 until 30 minutes before the end of the surgery. In Group E, 0.2mg/kg esketamine was infused intravenously before the induction of anesthesia for 10 min, and then maintained at 0.15 mg·kg-1·h-1 until 30 minutes before the end of the surgery. The primary outcome measures of this study were the oxygenation index (OI) at the following time points: before one-lung ventilation (OLV) (T1), 30 minutes after OLV initiation (T2), and 60 minutes after OLV initiation (T3). The secondary outcome measures included: (1)The duration of OLV, blood loss, fluid infusion volume, the dosages of propofol, remifentanil and vasoactive drugs(ephedrine and atropine) were recorded in each group.(2)Heart rate (HR) and mean arterial pressure (MAP) were recorded at the following time points: upon entering the operating room (T0), before OLV (T1), 30 minutes after OLV initiation (T2), 60 minutes after OLV initiation (T3), before extubation (T4), and 5 minutes after extubation (T5).(3)Blood gas anlaysis parameters,airway plateau pressure,tidal volume and positive end-expiratory pressure were recorded from T1 to T3，and dynamic lung compliance and intrapulmonary shunt fraction were calculated.(4) White blood cell counts, neutrophil percentage,and C-reactive protein (CRP) levels were recorded preoperatively and 24 hours postoperatively.(5)Postoperative pain was evaluated using the visual analogue score (VAS) at 2, 6, 12, and 24 hours after surgery, and the number of patients requiring rescue analgesia in each group was recorded. The occurrence of postoperative adverse reactions and postoperative pulmonary complications (PCCs) within one week after surgery were recorded. The postoperative quality of recovery was evaluated using the QOR-15 scale at 24 and 48 hours after surgery,and the postoperative hospital stay was recorded.
Background：According to the cancer statistics report released by the American Cancer Society in 2024, about one in five people will develop cancer in lifetime, and about one in nine men and one in twelve women will die of cancer. Lung cancer is the most commonly occurring cancer worldwide (accounting for 1.4% of all new cases) and is also the leading cause of cancer death (accounting for 18.7% of total cancer deaths), nearly twice second leading cause of cancer death.At present, surgery is the preferred treatment for early-stage lung cancer, and timely and effective surgical treatment can effectively reduce risk of tumor recurrence and metastasis, and improve the survival rate of patients.With the continuous development of modern medical technology, the surgical approach for lung cancer has evolved from traditional open thoracotomy to video-assisted thor surgery (VATS). As a minimally invasive surgery, VATS has many advantages, such as small incision, rapid postoperative recovery, and fewer postoperative. VATS usually requires the use of a double-lumen endobronchial tube (DLT) or a bronchial blocker to perform one-lung (OLV) on the nonoperative side. OLV is a ventilation technique that separates the ventilation pathways of both sides at the level of the carina. The is to collapse the surgical side of the lung and protect the nonoperative side of the lung from contamination, while also facilitating the exposure of the surgical field and reducing the of surgical complications.However,during OLV, the atelectatic lung, although not ventilated, still has blood flow through it, and this blood is not oxygenated, in a mismatch in the ventilation/perfusion ratio (VA/Q), leading to an increase in intrapulmonary shunting and a decrease in oxygenation, which in leads to hypoxemia.Secondly, thoracic surgery is generally performed in the lateral position, and due to the influence of gravity, the patient's ventilation and blood flow distribution uneven, with the shunt fraction reaching as high as 40-50%.Hypoxia and ischemic injury as well as cellular damage can be caused by insufficient ventilation. During the process of restoring blood supply, will also aggravate cellular damage, cause pathological and physiological changes in the lung, trigger ischemia-reperfusion injury, hypoxemia, and then acute inflammatory response oxidative stress response, causing acute injury to a variety of organs. In recent years, with the implementation of lung-protective ventilation strategy, the application and popularization fiberoptic bronchoscopy and video double-lumen bronchial intubation, the incidence of hypoxemia has decreased, but the incidence in thoracic is still 10% to 25%.Strategies to improve hypoxemia include pharmacological reduction of intrapulmonary shunt, improvement of ventilation-perfusion mismatch, and improvement of strategies . The strategy of ventilating the surgical lung is not conducive to the collapse of the surgical lung during thoracoscopy, affecting the exposure of the field. At present, the use of pharmacological intervention is a new idea in the study of improving hypoxemia during OLV of thoracoscopy.
Esketamine, as a new type of intravenous anesthetic, is a high-affinity N-methyl-D-aspartate (NA) receptor non-competitive inhibitor. As the S-enantiomer of ketamine, it has a similar mechanism of action to ketamine, but with a higher for the NMDA receptor and a potency twice that of ketamine. Therefore, compared with traditional ketamine, a smaller dose can achieve the desired anesthetic effect while reducing the incidence of psychotropic side effects. Its effects can produce analgesia, sedation, anti-inflammation, anti-depression, mild respiratory depression and mild circulatory excitation.Esketamine can directly act on the airway smooth muscle, dilate the bronchi and relax the airway through voltage-dependent L-type calcium, effectively relieve bronchospasm, reduce airway resistance, improve lung compliance, and improve ventilation and gas exchange function.Meanwhile, esketamine can inhibit the release of inflammatory cells stimulated by oxygen free radicals, reduce the secretion of various cytokines such as TNFα, IL-6 and IL-8 by white blood cells, inhibit the expression of adhesion factors on the surface of neutrophils and the activity of induc nitric oxide synthase, and promote the secretion of anti-inflammatory cytokines, which can play a multi-level antagonistic role in inflammation.Many studies have suggested that esmolol may be a potential drug intervention to improve perioperative oxygenation.
Dexmedetomidine is a highly selective α2-adrenergic receptor agonist, which mainly produces sedative, analgesic,-anxiety, and sympatholytic effects by acting on the central nervous system, peripheral nervous system, and other organ tissues.Recent studies have shown that dexmedetomidine can reduce the inflammatory response and oxidative stress of thoracic surgery by reducing the levels of plasma,-6, IL-8, TNF-α, and lipid peroxidation in patients, improve the expression of aquaporin in lung tissue of thoracic, increase the concentration of nitric oxide in the blood, dilate the pulmonary vessels on the ventilated side, and effectively reduce intrapulmonary shunting and oxygenation.In addition, dexmedetomidine can directly enhance HPV by targeting α2B receptors in vascular smooth muscle and inducing vasoconstriction in the nonventilated lung, improving the intraoperative oxygenation index, reducing dead space ventilation, improving the dynamic compliance of the lung, and reducing the incidence of postoperative, playing an important role in lung protection.
Based on the above research on esmolol, this study will explore the effects of esmolol on patients' oxygenation and intrapul shunting during single-lung ventilation in thoracoscopy surgery on the basis of previous research, and further clarify the advantages of esmolol in thoracoscopy surgery and provide new clinical basis for optimizing the lung protection strategy during single-lung ventilation in thoracoscopy surgery patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Esketamine
In Group E, 0.2mg/kg esketamine was infused intravenously before the induction of anesthesia for 10 min, and then maintained at 0.15 mg·kg-1·h-1 until 30 minutes before the end of the surgery.
Esketamine
A total of 126 patients undergoing thoracoscopic surgery under elective general anesthesia were randomly divided into three groups: normal saline group (group C), dexmedetomidine group (group D), eschloroacetone group (group E) and dexmedetomidine group (group D), with 42 cases in each group. Group C was continuously injected with the same amount of normal saline, group D was given dextrometin 1 ug/kg load 10min before surgery, and maintained at 0.4 ug/kg\*h after intubation until 30min before the end of surgery. Group E was given esketamine 0.2 mg/kg 10min before surgery, and maintained at 0.15 mg/kg\*h after intubation until 30min before surgery. Other anesthetic induction and maintenance drugs were consistent among the three groups.
Dexmedetomidine
Group D was given 1 ug/kg of dexmedetomidine 10min before surgery, and maintained at 0.4 ug/kg\*h after intubation until 30min before the end of surgery
Dexmedetomidine
group D was given Dexmedetomidine 1 ug/kg load 10min before surgery, and maintained at 0.4 ug/kg\*h after intubation until 30min before the end of surgery.
Normal saline
Group C continued to pump the same amount of normal saline
Normal Saline
Group C was continuously injected with the same amount of normal saline,
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Esketamine
A total of 126 patients undergoing thoracoscopic surgery under elective general anesthesia were randomly divided into three groups: normal saline group (group C), dexmedetomidine group (group D), eschloroacetone group (group E) and dexmedetomidine group (group D), with 42 cases in each group. Group C was continuously injected with the same amount of normal saline, group D was given dextrometin 1 ug/kg load 10min before surgery, and maintained at 0.4 ug/kg\*h after intubation until 30min before the end of surgery. Group E was given esketamine 0.2 mg/kg 10min before surgery, and maintained at 0.15 mg/kg\*h after intubation until 30min before surgery. Other anesthetic induction and maintenance drugs were consistent among the three groups.
Dexmedetomidine
group D was given Dexmedetomidine 1 ug/kg load 10min before surgery, and maintained at 0.4 ug/kg\*h after intubation until 30min before the end of surgery.
Normal Saline
Group C was continuously injected with the same amount of normal saline,
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-65 years old;
* BMI18\~30 kg/m2;
* American Society of Anesthesiologistsgrade I\~III;
* No contraindications to drugs;
* All patients and their families agreed to participate in this study and signed informed consent
Exclusion Criteria
* Respiratory infection and non-steroidal anti-inflammatory drugs or hormone drugs taken within 2 weeks before surgery;
* severe liver and kidney dysfunction and immune system diseases, uncontrolled hypertension, diabetes;
* History of preoperative chemoradiotherapy.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jinqiao Qian
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jinqiao Qian
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Shi J, Yu T, Song K, Du S, He S, Hu X, Li X, Li H, Dong S, Zhang Y, Xie Z, Li C, Yu J. Dexmedetomidine ameliorates endotoxin-induced acute lung injury in vivo and in vitro by preserving mitochondrial dynamic equilibrium through the HIF-1a/HO-1 signaling pathway. Redox Biol. 2021 May;41:101954. doi: 10.1016/j.redox.2021.101954. Epub 2021 Mar 21.
Xie Y, Jiang W, Zhao L, Wu Y, Xie H. Effect of dexmedetomidine on perioperative inflammation and lung protection in elderly patients undergoing radical resection of lung cancer. Int J Clin Exp Pathol. 2020 Oct 1;13(10):2544-2553. eCollection 2020.
Cai SY, Liu A, Xie WX, Zhang XQ, Su B, Mao Y, Weng DG, Chen ZY. Esketamine mitigates mechanical ventilation-induced lung injury in chronic obstructive pulmonary disease rats via inhibition of the MAPK/NF-kappaB signaling pathway and reduction of oxidative stress. Int Immunopharmacol. 2024 Sep 30;139:112725. doi: 10.1016/j.intimp.2024.112725. Epub 2024 Jul 25.
Tu W, Yuan H, Zhang S, Lu F, Yin L, Chen C, Li J. Influence of anesthetic induction of propofol combined with esketamine on perioperative stress and inflammatory responses and postoperative cognition of elderly surgical patients. Am J Transl Res. 2021 Mar 15;13(3):1701-1709. eCollection 2021.
Campos JH, Feider A. Hypoxia During One-Lung Ventilation-A Review and Update. J Cardiothorac Vasc Anesth. 2018 Oct;32(5):2330-2338. doi: 10.1053/j.jvca.2017.12.026. Epub 2017 Dec 19. No abstract available.
Durkin C, Romano K, Egan S, Lohser J. Hypoxemia During One-Lung Ventilation: Does It Really Matter? Curr Anesthesiol Rep. 2021;11(4):414-420. doi: 10.1007/s40140-021-00470-5. Epub 2021 Jul 7.
Lumb AB, Slinger P. Hypoxic pulmonary vasoconstriction: physiology and anesthetic implications. Anesthesiology. 2015 Apr;122(4):932-46. doi: 10.1097/ALN.0000000000000569.
Archer SL, Dunham-Snary KJ, Bentley R, Alizadeh E, Weir EK. Hypoxic Pulmonary Vasoconstriction: An Important Component of the Homeostatic Oxygen Sensing System. Physiol Res. 2024 Nov 29;73(S2):S493-S510. doi: 10.33549/physiolres.935431.
Alday E, Nieves JM, Planas A. Oxygen Reserve Index Predicts Hypoxemia During One-Lung Ventilation: An Observational Diagnostic Study. J Cardiothorac Vasc Anesth. 2020 Feb;34(2):417-422. doi: 10.1053/j.jvca.2019.06.035. Epub 2019 Jun 28.
Nierengarten MB. Global cancer statistics 2022: The report offers a view on disparities in the incidence and mortality of cancer by sex and region worldwide and on the areas needing attention. Cancer. 2024 Aug 1;130(15):2568. doi: 10.1002/cncr.35444. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CXPJJH124001-19
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
(2024)ethical review L No.122
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.